Hangzhou Hanx Biopharmaceuticals, Ltd.
Clinical trials sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd., explained in plain language.
-
New antibody HX009 shows promise for tough lymphoma cases
Disease control CompletedThis study tested a new drug called HX009 in 48 Chinese patients with lymphoma that had relapsed or not responded to prior treatments. HX009 is a dual-target antibody designed to block two proteins (CD47 and PD-1) that help cancer cells hide from the immune system. The goal was t…
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC